Institute of Biomedical Research Corp. (MRES)
USD 0.01
(5.38%)
USD 0.01
(5.38%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2010 | -273.4 Thousand USD | 38.32% |
| 2009 | -443.28 Thousand USD | 91.74% |
| 2008 | -5.36 Million USD | -677.52% |
| 2007 | -690.29 Thousand USD | -290.26% |
| 2006 | -176.88 Thousand USD | 0.0% |
| 2004 | -20.14 Thousand USD | -36.7% |
| 2003 | -14.73 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2010 Q2 | -50.08 Million USD | -42133.09% |
| 2010 Q3 | -76.91 Thousand USD | 99.85% |
| 2010 Q4 | -55.68 Thousand USD | 27.6% |
| 2010 Q1 | -118.58 Thousand USD | -16.22% |
| 2010 FY | -273.4 Thousand USD | 38.32% |
| 2009 Q2 | -31.6 Thousand USD | 78.93% |
| 2009 FY | -443.28 Thousand USD | 91.74% |
| 2009 Q3 | -21.18 Thousand USD | 32.97% |
| 2009 Q1 | -150.01 Thousand USD | -63.93% |
| 2009 Q4 | -102.03 Thousand USD | -381.66% |
| 2008 Q1 | -4.72 Million USD | -2471.71% |
| 2008 Q4 | -91.51 Thousand USD | 3.73% |
| 2008 Q3 | -95.05 Thousand USD | 10.93% |
| 2008 Q2 | -106.71 Thousand USD | 97.74% |
| 2008 FY | -5.36 Million USD | -677.52% |
| 2007 Q2 | -148.96 Thousand USD | 77.51% |
| 2007 FY | -690.29 Thousand USD | -290.26% |
| 2007 Q4 | -183.86 Thousand USD | 38.38% |
| 2007 Q3 | -298.37 Thousand USD | -100.3% |
| 2007 Q1 | -662.29 Thousand USD | -10616.81% |
| 2006 FY | -176.88 Thousand USD | 0.0% |
| 2006 Q4 | -6180.00 USD | 63.82% |
| 2006 Q3 | -17.08 Thousand USD | -201.23% |
| 2006 Q2 | -5671.00 USD | -107.19% |
| 2006 Q1 | 78.86 Thousand USD | 168.32% |
| 2005 Q3 | -12.14 Thousand USD | -58.4% |
| 2005 Q4 | -115.42 Thousand USD | -850.05% |
| 2005 Q2 | -7670.00 USD | -204.97% |
| 2005 Q1 | -2515.00 USD | 28.1% |
| 2004 Q3 | -2572.00 USD | 70.39% |
| 2004 Q2 | -8686.00 USD | -85.64% |
| 2004 FY | -20.14 Thousand USD | -36.7% |
| 2004 Q4 | -3498.00 USD | -36.0% |
| 2004 Q1 | -4679.00 USD | 0.0% |
| 2003 FY | -14.73 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 79.527% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 96.085% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.516% |
| Nascent Biotech, Inc. | -2.08 Million USD | 86.904% |
| Rebus Holdings, Inc. | -1.02 Million USD | 73.196% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.42% |
| Qrons Inc. | -789.34 Thousand USD | 65.364% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 56.768% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 99.563% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 34.196% |
| Skye Bioscience, Inc. | -37.64 Million USD | 99.274% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.635% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 95.842% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.656% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 90.548% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 84.982% |
| Mesoblast Limited | -87.95 Million USD | 99.689% |
| Marizyme, Inc. | -65.34 Million USD | 99.582% |
| Genus plc | 7.9 Million USD | 103.461% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 97.49% |
| Pharming Group N.V. | -10.54 Million USD | 97.408% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 87.4% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 92.631% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 96.909% |
| ContraFect Corporation | -65.15 Million USD | 99.58% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 94.404% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 84.173% |
| IMV Inc. | -36.48 Million USD | 99.251% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 96.608% |
| MultiCell Technologies, Inc. | -380.07 USD | -71834.644% |
| ONE Bio Corp. | 8.67 Million USD | 103.151% |
| Accustem Sciences Inc. | -3.74 Million USD | 92.702% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 99.471% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 78.424% |
| Q BioMed Inc. | -2.05 Million USD | 86.677% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 92.676% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 88.517% |
| Biomind Labs Inc. | -1.21 Million USD | 77.485% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 99.542% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 91.186% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 96.541% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 85.974% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -1725.601% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 98.277% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 95.3% |
| GB Sciences, Inc. | -1.36 Million USD | 79.922% |
| Alpha Cognition Inc. | -13.77 Million USD | 98.015% |
| HST Global, Inc. | -146.21 Thousand USD | -86.993% |
| CSL Limited | 2.64 Billion USD | 100.01% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 84.42% |
| Halberd Corporation | -79.67 Thousand USD | -243.142% |
| Enzolytics Inc. | -2.17 Million USD | 87.44% |
| Agentix Corp. | -1.37 Million USD | 80.105% |
| Resverlogix Corp. | -3.61 Million USD | 92.427% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 91.379% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.907% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 378.982% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 103.948% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 93.118% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 90.965% |
| AVAX Technologies, Inc. | -6.41 Million USD | 95.737% |
| Zenith Capital Corp. | -10.59 Million USD | 97.42% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.714% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -1076.327% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 93.406% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -352.348% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 86.365% |
| Kadimastem Ltd | -3.3 Million USD | 91.734% |
| Helix BioMedix, Inc. | -1.05 Million USD | 74.111% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 92.841% |
| BioStem Technologies, Inc. | -8.48 Million USD | 96.777% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 38.056% |
| LadRx Corporation | 400.44 Thousand USD | 168.275% |
| Cell Source, Inc. | -5.32 Million USD | 94.862% |
| Regen BioPharma, Inc. | 1.02 Million USD | 126.712% |
| Regen BioPharma, Inc. | 1.02 Million USD | 126.712% |
| NovAccess Global Inc. | -4.76 Million USD | 94.267% |
| Affymax, Inc. | -14.42 Million USD | 98.105% |
| Itoco Inc. | -1.86 Million USD | 85.372% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 93.846% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 83.619% |
| Mobile Lads Corp. | -2.26 Million USD | 87.92% |
| CytoDyn Inc. | -49.84 Million USD | 99.451% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -245.934% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -19.846% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 70.962% |
| SYBLEU INC | -180.3 Thousand USD | -51.634% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 83.047% |
| International Stem Cell Corporation | -131 Thousand USD | -108.704% |
| Bioxytran, Inc. | -4.28 Million USD | 93.612% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -403.763% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 89.195% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 99.431% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 87.067% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 64.988% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 91.37% |
| Neutra Corp. | -233.46 Thousand USD | -17.106% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 98.653% |
| PureTech Health plc | -65.69 Million USD | 99.584% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 98.714% |
| IXICO plc | -1.17 Million USD | 76.791% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 97.246% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 99.521% |
| CSL Limited | 2.64 Billion USD | 100.01% |
| Cellectis S.A. | -103.17 Million USD | 99.735% |